source
- Novo acquires three early-stage obesity assets from Kallyope to broaden pipeline amid investor pressureInvestors have been urging Novo to expand its pipeline beyond the semaglutide franchise that drives most of its sales. In response, Novo announced it will acquire three early-stage obesity candida…
- Alkermes' orexin agonist ALKS 7290 shows promise in early-stage ADHD trialAlkermes reported results from a Phase 1 study of its orexin agonist ALKS 7290, a drug class previously explored for rare sleep disorders. The trial enrolled adults with moderate to severe ADHD, a…